Search results
For over 35 years Parexel has been a trusted global CRO and biopharmaceutical services company. Learn more about how we can help.
- Careers
Transform healthcare, trial new treatments, and reinvent...
- 日本
Parexel...
- Contact Us
Need to expedite your development journey? Parexel is here...
- Biotech Solutions
Leveraging our dedicated biotech operations group, we match...
- Volunteer
Clinical trials are vital for the development of new,...
- Early Development and Innovation
At Parexel, we’re perfectly positioned with fully integrated...
- FSP Delivery Models
Our translational medicine group -- comprised of scientific...
- Integrated Clinical Development
At Parexel, we combine a comprehensive portfolio of medical...
- Careers
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help lifesaving treatments reach patients faster.
Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process.
Clinical trials are vital for the development of new, medicines — but they rely upon volunteers to succeed. Here you’ll learn more about our clinical trials, what it’s like to participate, and how you may be able to help improve treatment options for patients.
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients...
12 sie 2024 · Parexel and Palantir announced a multi-year strategic partnership to leverage artificial intelligence to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharmaceutical customers.
2 lip 2021 · BOSTON and Durham, N.C. July 2, 2021 — Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund (“EQT Private Equity”) and the ...
